

Sarcoma Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



Sarcoma

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

First Line

Second Line

Recurrent

UCI 21-03
Pembrolizumab + Stereotactic Body Radiation Therapy
Coord: N. Arechiga
Accrual: 6/8

EA7211
Surgery + Doxorubicin, Ifosfamide or
Doxorubicin, Decarbazine
Coord: B. Huynh
Accrual: 0/5

ETCTN 10556
Ipilimumab and Nivolumab +/-
Cabozantinib
Coord: B. Huynh
Accrual: 1/5